Key Highlights
- Total Revenue was about USD 35 million, up 6.3% from the second quarter.
- LucentAD tests sold more than doubled sequentially in the third quarter.
- Florida Medicaid reimbursement for LucentAD Complete was finalized at USD 480 per test.
- Accelerator Lab bookings grew for a second quarter, with book-to-bill approaching 2x.
Quanterix Corporation (NASDAQ:QTRX) reported third quarter 2026 total revenue of approximately USD 35 million, up 6.3% from the second quarter and 13.1% below the USD 40.2 million reported in the third quarter of 2025. Reported EPS was negative USD 0.46 and revenue was USD 34.97 million, compared with estimates of EPS of negative USD 0.42 and revenue of USD 33.85 million.
On a pro forma basis, excluding USD 2.4 million of third quarter 2025 revenue from a terminated diagnostic development program and including USD 0.6 million of Akoya pre-acquisition revenue, the year-over-year decline was 8.6%. The company's chief financial officer said the result does not reflect the full impact of new Leadership and the reprioritization of the commercial organization, which began midway through the quarter.
Commercial Performance
Chief executive Everett Cunningham said the commercial teams performed better across the board despite continued market softness, with sequential growth across all product categories and technology platforms. The Accelerator Lab grew bookings for the second consecutive quarter at a book-to-bill approaching 2x, and a new dedicated sales team, now about 20 people, is building long-term relationships, including through custom assay development services.
Management said the company exceeded its own expectations for Top Line performance and that recent assay launches and upcoming plant expansions address customer needs that drive use of the installed instrument base, as seen in consumable growth in the quarter.
Diagnostics and Florida Coverage
LucentAD tests sold more than doubled from the second quarter, which management tied to commercial partnerships. The company signed partnerships with two clinical reference labs: Sherman Abrams in the New York and New Jersey tri-state area and TruPath in Mississippi, spanning more than 14 states.
Under Florida House Bill 885, Florida's Medicaid administrator approved coverage of blood-based biomarker testing for Alzheimer's disease, such as LucentAD Complete, when medical necessity criteria are met, effective November 1. Reimbursement was finalized at USD 480 per test, and coverage applies retroactively to July 2026. Over 4 million Florida residents are eligible for Medicaid. Management said clinical Utility studies involving its five biomarker tests are progressing, that publication of completed studies by three major health organizations is awaited, and that discussions with the FDA on the five biomarker tests have continued.
Product Developments
On the Simoa platform, the company launched ApoE4 prototyping and IL-18 kits in the quarter. The ApoE4 assay distinguishes noncarriers, heterozygotes and homozygotes, which are linked to Alzheimer's risk and to side effects associated with anti-amyloid therapies. The IL-18 assay addresses the role of neuroinflammation in Alzheimer's, with broader application in inflammation and oncology.
The company's planned 510(k) submission for the HD-X instrument as an in vitro diagnostic is progressing with its third-party contract manufacturer, with a goal of a 2027 submission. In spatial biology, the PhenoCode 2.0 Molecular Barcoding Kit is in full commercial release. Two further panels ship in early 2027: the TIME panel, covering the tumor immune microenvironment, and a high-plex antibody drug conjugate panel.
Management said it is expanding its spatial oncology panel offering around the hallmarks of cancer framework and sees an opportunity to increase spatial consumable growth, as it did in the third quarter.
Management said its diagnostics Business is readying its platform to scale and support expansion of LucentAD Complete testing in 2027, and that the data points support its outlook for the remainder of 2026 and growth continuing in 2027. The company described its third quarter results as an early proof point in its path to restoring growth.
Product Timelines and Coverage
Quanterix reported LucentAD tests sold more than doubling sequentially and Florida Medicaid reimbursement of USD 480 per test. Management cited early 2027 shipment of the TIME and antibody drug conjugate panels, a 2027 HD-X 510(k) submission goal, clinical utility publications and extension of blood based biomarker coverage to other states.




_11_19_2026_18_08_46_525309.jpg)

Please wait processing your request...